Literature DB >> 26403663

Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study.

Raphaële Renard-Penna1,2, Morgan Roupret3,4, Eva Compérat5,4, François Rozet6, Benjamin Granger7, Johann Barkatz3, Marc Olivier Bitker3, Olivier Lucidarme8, Olivier Cussenot9,4, Pierre Mozer3,4.   

Abstract

OBJECTIVES: To assess whether non-suspicious multiparametric magnetic-resonance imaging (mpMRI) was associated with no cancer or indolent prostate cancer (PCa) in subsequent biopsies. PATIENTS AND METHODS: Retrospective analyses of a prospective database were conducted between 2009 and 2013. It included men with an abnormal digital rectal examination and/or prostate-specific antigen levels <20 ng/mL and a non-suspicious multiparametric MRI (Likert score <3). Participants underwent a systematic 12-extended-core biopsy ultrasound protocol (STD). Indolent PCa was defined as a single core with a Gleason score of 6 (3 + 3) and a cancer-core length of ≤4 mm.
RESULTS: Seventy-eight patients with a negative MRI were included in the study; median patient age was 62 years (IQR 50-74). Median PSA level was 7.15 ng/mL, with a median PSA density of 0.15. The digital rectal examination was abnormal in eight cases. From MRI, 53 patients were Likert 2, 25 patients were Likert 1, and median prostate volume was 56.5 mL. From biopsies, no cancer was found in 92.3 % (n = 72). PCa was histologically confirmed in six patients (7.7 %): five cases were indolent (as defined above); only one patient had a cancer core of 5 mm long, with a Gleason score of 6 (3 + 3). All six patients were within the low-risk group according to the D'Amico classification.
CONCLUSION: Men with non-suspicious mpMRI are likely to have no or indolent PCa in subsequent biopsies.

Entities:  

Keywords:  Biopsy; Gleason score; MRI; Prostate neoplasms; Prostate-specific antigen

Mesh:

Year:  2015        PMID: 26403663     DOI: 10.1007/s00345-015-1685-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  31 in total

1.  Prostate biopsy tracking with deformation estimation.

Authors:  Michael Baumann; Pierre Mozer; Vincent Daanen; Jocelyne Troccaz
Journal:  Med Image Anal       Date:  2011-05-17       Impact factor: 8.545

2.  What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?

Authors:  Pieter Julien Luc De Visschere; Leslie Naesens; Louis Libbrecht; Charles Van Praet; Nicolaas Lumen; Valérie Fonteyne; Eva Pattyn; Geert Villeirs
Journal:  Eur Radiol       Date:  2015-07-03       Impact factor: 5.315

3.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

4.  Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy.

Authors:  Sarah J Drouin; Eva Comperat; Olivier Cussenot; Marc-Olivier Bitker; Alain Haertig; Morgan Rouprêt
Journal:  Urol Oncol       Date:  2010-10-02       Impact factor: 3.498

Review 5.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

6.  First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer.

Authors:  Pierre Mozer; Morgan Rouprêt; Chloé Le Cossec; Benjamin Granger; Eva Comperat; Arachk de Gorski; Olivier Cussenot; Raphaële Renard-Penna
Journal:  BJU Int       Date:  2014-07-27       Impact factor: 5.588

7.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Authors:  James E Thompson; Daniel Moses; Ron Shnier; Phillip Brenner; Warick Delprado; Lee Ponsky; Marley Pulbrook; Maret Böhm; Anne-Maree Haynes; Andrew Hayen; Phillip D Stricker
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

8.  Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.

Authors:  Olivier Cussenot; Jean-Nicolas Cornu; Sarah J Drouin; Pierre Mozer; Christophe Egrot; Christophe Vaessen; François Haab; Marc-Olivier Bitker; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

Review 9.  Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer.

Authors:  Ashley J Ridout; Veeru Kasivisvanathan; Mark Emberton; Caroline M Moore
Journal:  Int J Urol       Date:  2013-09-03       Impact factor: 3.369

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  3 in total

1.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

Review 2.  Score 3 prostate lesions: a gray zone for PI-RADS v2.

Authors:  Michele Scialpi; Eugenio Martorana; Maria Cristina Aisa; Valeria Rondoni; Alfredo D'Andrea; Giampaolo Bianchi
Journal:  Turk J Urol       Date:  2017-08-03

Review 3.  Is contrast enhancement needed for diagnostic prostate MRI?

Authors:  Michele Scialpi; Valeria Rondoni; Maria Cristina Aisa; Eugenio Martorana; Alfredo D'Andrea; Corrado Maria Malaspina; Agostino Orlandi; Giorgio Galassi; Emanuele Orlandi; Pietro Scialpi; Michele Dragone; Diego Palladino; Annalisa Simeone; Michele Amenta; Giampaolo Bianchi
Journal:  Transl Androl Urol       Date:  2017-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.